Cargando…

Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and 1p/19q codeleted oligodendroglioma

BACKGROUND: Optimal management for recurrent IDH-mutant glioma after radiation therapy (RT) is not well-defined. This study assesses practice patterns for managing recurrent IDH-mutant astrocytoma (Astro) and 1p/19q codeleted oligodendroglioma (Oligo) after RT and surveys their clinical outcomes aft...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Sirui, Rudra, Soumon, Campian, Jian L, Chheda, Milan G, Johanns, Tanner M, Ansstas, George, Abraham, Christopher D, Chicoine, Michael R, Leuthardt, Eric C, Dowling, Joshua L, Dunn, Gavin P, Kim, Albert H, Huang, Jiayi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324173/ https://www.ncbi.nlm.nih.gov/pubmed/34345818 http://dx.doi.org/10.1093/noajnl/vdab081

Ejemplares similares

Treating oligodendroglioma – An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort
por: Allwohn, Luisa, et al.
Publicado: (2023)

Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma
por: Ma, Sirui, et al.
Publicado: (2020)

Naturopathic Treatment of Grade III Oligodendroglioma With Progression to Grade IV Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma and the Development of Spinal Gliomatosis
por: Terrani, Kristina F, et al.
Publicado: (2023)

Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
por: Gwak, Ho-Shin, et al.
Publicado: (2013)

Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma
por: Lai, Grace, et al.
Publicado: (2015)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion
por: Chen, Sean Chun-Chang, et al.
Publicado: (2019)

Conventional and emerging treatments of astrocytomas and oligodendrogliomas
por: Kessler, Tobias, et al.
Publicado: (2022)

Chromatin-regulating genes are associated with postoperative prognosis and isocitrate dehydrogenase mutation in astrocytoma
por: Zhang, Kun, et al.
Publicado: (2020)

Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
por: Hassan, Usman, et al.
Publicado: (2023)

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
por: Ducray, François, et al.
Publicado: (2008)

Case report: Spinal drop metastasis of IDH-mutant, 1p/19q-codeleted oligodendroglioma
por: Karaman, Ahmet Kursat, et al.
Publicado: (2022)

Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation
por: Ferreira, Monica Sofia Ventura, et al.
Publicado: (2020)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas
por: Sahu, Arpita, et al.
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database
por: Zreik, Jad, et al.
Publicado: (2021)

A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma
por: Butt, Omar H, et al.
Publicado: (2021)

Corrigendum to: A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma
por: Butt, Omar H, et al.
Publicado: (2022)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

CeRNA Network Analysis Representing Characteristics of Different Tumor Environments Based on 1p/19q Codeletion in Oligodendrogliomas
por: Ahn, Ju Won, et al.
Publicado: (2020)

Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2
por: Merchant, Mythili, et al.
Publicado: (2022)

Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases
por: Kim, Jo-Heon, et al.
Publicado: (2019)

Immunodetection of Pyruvate Carboxylase Expression in Human Astrocytomas, Glioblastomas, Oligodendrogliomas, and Meningiomas
por: Gondáš, Eduard, et al.
Publicado: (2023)

Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report
por: Burgy, Mickaël, et al.
Publicado: (2019)

A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas
por: Gilhodes, Julia, et al.
Publicado: (2023)

Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
por: Khaddour, Karam, et al.
Publicado: (2020)

Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
por: Khaddour, Karam, et al.
Publicado: (2023)

The feasibility of MRI texture analysis in distinguishing glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma
por: Teng, Yuen, et al.
Publicado: (2022)

Oligodendrogliomas tend to infiltrate the frontal aslant tract, whereas astrocytomas tend to displace it
por: Landers, M. J. F., et al.
Publicado: (2023)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta‐analysis based on a Cochrane systematic review
por: Brandner, Sebastian, et al.
Publicado: (2022)

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma
por: van Lith, Sanne A. M., et al.
Publicado: (2016)

The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions
por: Khaddour, Karam, et al.
Publicado: (2020)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
por: Khaddour, Karam, et al.
Publicado: (2021)

Theabrownin Induces Cell Apoptosis and Cell Cycle Arrest of Oligodendroglioma and Astrocytoma in Different Pathways
por: Fu, J. Y., et al.
Publicado: (2021)

Risk factors of extraneural spreading in astrocytomas and oligodendrogliomas in donors with gliomas: A systematic review
por: Ammendola, Serena, et al.
Publicado: (2022)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sgelpgcdqnqqi6fl9vv7nukcjo